RP-182 is a synthetic peptide analog that selectively induces conformational transitions of the mannose receptor CD206 expressed on M2-type TAMs, thus reprogramming M2-like TAMs to an anti-tumor M1-like TAM phenotype (83). The gene discussed is MRC1; the disease is neoplasm.